The U.S. Food and Drug Administration (FDA) granted initial approval to Liraglutide (ANDA 217234) for sponsor ORBICULAR on February 24, 2026. This approval signifies the availability of a generic version of the drug, expanding treatment options for conditions where Liraglutide is indicated.
Background
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is currently marketed under various brand names for the treatment of type 2 diabetes mellitus and for chronic weight management in adults and adolescents. As an Abbreviated New Drug Application (ANDA) approval, this signifies that ORBICULAR's Liraglutide is a generic drug product that is bioequivalent to its reference listed drug, ensuring it has the same quality, strength, purity, and stability.
What this means
The FDA's approval of ORBICULAR's Liraglutide as an ANDA is a significant development for patients and healthcare providers. ANDA approvals indicate that the generic drug is bioequivalent to its brand-name counterpart, meaning it works in the same way and provides the same clinical benefit. This approval is expected to increase patient access to Liraglutide by introducing a more affordable generic option, potentially leading to reduced healthcare costs and broader utilization of this important therapeutic agent in its approved indications.
Source
The U.S. Food and Drug Administration (FDA) announced the initial approval of Liraglutide (ANDA 217234) for ORBICULAR on February 24, 2026. This information is publicly available on the FDA's website, accessdata.fda.gov.